Alpha 2.0
Login Register
» Authors » Nikki Church

Nikki Church

Explore the profile of Nikki Church including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 6
Citations 19
Followers 0
Related Specialty
Hematology
Top 10 Co-Authors
Despina Tseneklidou-Stoeter
Horst Beckmann
Johnny N Mahlangu
Victor Blanchette
Olga Moshkovich
Monika Maas Enriquez
Yongqiang Zhao
Depei Wu
Ella X Du
Jipan Xie
Published In
J Blood Med
J Thromb Haemost
Ther Adv Hematol
Eur J Haematol
Haemophilia
Affiliations
Soon will be listed here.
Recent Articles
1.
Continued benefit demonstrated with BAY 81-8973 prophylaxis in previously treated children with severe haemophilia A: Interim analysis from the LEOPOLD Kids extension study
Kenet G, Ljung R, Rusen L, Kerlin B, Blanchette V, Trakymiene S, et al.
Thromb Res . 2020 Mar; 189:96-101. PMID: 32197139
Introduction: BAY 81-8973 (Kovaltry®), a recombinant factor VIII (rFVIII) product, was efficacious and well tolerated in paediatric previously treated patients (PTPs) with severe haemophilia A for ≥50 exposure days (EDs)...
2.
BAY 81-8973 demonstrated efficacy, safety and joint status improvement in patients with severe haemophilia A in the LEOPOLD I extension for ≤2 years
Mahlangu J, Lopez Fernandez M, Santagostino E, Lalezari S, Tseneklidou-Stoeter D, Beckmann H, et al.
Eur J Haematol . 2020 Mar; 104(6):594-601. PMID: 32112434
Objectives: BAY 81-8973 (Kovaltry ), a full-length, unmodified, recombinant human factor VIII, provided excellent bleeding control for patients with haemophilia A in the pivotal 1-year LEOPOLD I trial. The LEOPOLD...
3.
Validity and reliability of the Colorado Adult Joint Assessment Scale in adults with moderate-severe hemophilia A
Funk S, Engelen S, Benjamin K, Moshkovich O, Gentile B, Church N, et al.
J Thromb Haemost . 2019 Sep; 18(2):285-294. PMID: 31557391
Background: The Colorado Adult Joint Assessment Scale (CAJAS) is designed to assess joint health in adults with hemophilia. The CAJAS comprises nine items (swelling, muscle atrophy, axial deformity, crepitus, range...
4.
Efficacy and safety of prophylaxis with BAY 81-8973 in Chinese patients with severe haemophilia A enrolled in the LEOPOLD II trial
Yang R, Sun J, Zhao Y, Wang X, Wu D, Tseneklidou-Stoeter D, et al.
Haemophilia . 2019 Apr; 25(3):e153-e158. PMID: 30993836
Introduction: BAY 81-8973 (Kovaltry ) is a full-length, unmodified recombinant human factor VIII approved in China for prophylaxis and on-demand treatment in patients with haemophilia A. Limited access to FVIII...
5.
BAY 81-8973, a full-length recombinant factor VIII for the treatment of hemophilia A: product review
Mahlangu J, Ahuja S, Windyga J, Church N, Shah A, Schwartz L
Ther Adv Hematol . 2018 Jul; 9(7):191-205. PMID: 30013766
BAY 81-8973 (Kovaltry) is an unmodified, full-length recombinant factor VIII (rFVIII) approved for the prevention and treatment of bleeding episodes in patients with hemophilia A. The amino acid sequence for...
6.
Matching-adjusted indirect comparisons of efficacy of BAY 81-8973 vs two recombinant factor VIII for the prophylactic treatment of severe hemophilia A
Pocoski J, Li N, Ayyagari R, Church N, Maas Enriquez M, Xiang Q, et al.
J Blood Med . 2016 Jul; 7:129-37. PMID: 27445511
Background: No head-to-head trials comparing recombinant factor VIII (rFVIII) products currently exist. This was a matching-adjusted indirect comparison (MAIC) study of efficacy of BAY 81-8973 with antihemophilic factor (recombinant) plasma/albumin-free...